Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
0.4075(c) 0.413(c) 0.404(c) 0.401(c) 0.3995 Last
277 280 209 297 202 589 192 621 548 504 Volume
-1.45% +1.35% -2.18% -0.74% -0.37% Change
More quotes
Financials (EUR)
Sales 2018 8,00 M
EBIT 2018 -7,03 M
Net income 2018 -8,06 M
Finance 2018 25,8 M
Yield 2018 -
Sales 2019 9,73 M
EBIT 2019 -4,02 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,46x
Capi. / Sales2019 3,03x
Capitalization 29,5 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
03/30NEOVACS : Provides corporate update and reports full-year 2017 financial results
GL
03/30NEOVACS : Provides corporate update and reports full-year 2017 financial results
AQ
03/27NEOVACS SA : annual earnings release
03/13NEOVACS : Phase 2b Trial of Neovacs Investigational Lupus Immunotherapy on Track..
AQ
02/22NEOVACS : Strengthens its intellectual property in the usa
GL
02/16NEOVACS : 2018 Financial Calendar
GL
02/14NEOVACS : Announces Positive Data Review from Last IDSMB Review Prior to Final R..
AQ
02/13NEOVACS : Announces Positive Data Review from Last IDSMB Review...
PU
02/13NEOVACS : Announces Positive Data Review from Last IDSMB Review Prior to Final R..
GL
01/16NEOVACS : Strengthened its intellectual property in russia...
PU
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/30NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULT.. 
02/13Neovacs : Announces Positive Data Review from Last IDSMB Review Prior to Fina.. 
2017NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR...  
2017Neovacs : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID.. 
2017Neovacs : announces free allocations of redeemable share...  
More tweets
Qtime:31
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,48 €
Spread / Average Target 269%
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Daniel Zagury Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-12.83%36
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873